Stop applying one-size-fits-all rules to conditions that demand precision
At a major Brazilian gynecology congress in May 2026, specialists gathered not merely to exchange protocols, but to dismantle the comfortable certainty of universal rules. Across six clinical cases — from adolescent amenorrhea to premature ovarian insufficiency — the recurring lesson was that medicine's most dangerous myths are often its most convenient ones. The panel's deeper argument was philosophical as much as clinical: that the individual patient is always the exception that tests the rule.
- Outdated clinical rules — like waiting until age 16 to investigate amenorrhea — are actively delaying care for girls who already have a known diagnosis like Turner syndrome.
- Conditions as distinct as premature ovarian insufficiency and natural menopause are being conflated, leading to undertreated younger women who need sustained hormonal support, not a waiting game.
- Surgically menopausal women with endometriosis are being made to suffer through hot flashes and night sweats based on a prescribed waiting period that specialists say has no clinical basis.
- Even higher-risk populations — women with lupus or polycystic ovary syndrome — are being navigated toward safer, individualized options rather than blanket exclusion from hormone therapy.
- The congress in Belo Horizonte is pushing gynecologists to replace reflexive protocol with precision: the evidence exists, but it must be applied to the specific woman in the room.
At the 63rd Brazilian Congress of Gynecology and Obstetrics, held in Belo Horizonte in late May 2026, a specialist panel led by Edmund Baracat of the University of São Paulo worked through six clinical cases in hormone therapy — each one chosen to expose a myth masquerading as standard practice.
The first case was a teenager with Turner syndrome who had never menstruated. The conventional rule says to wait until age 16 before investigating primary amenorrhea, but presenter Ana Carolina Japur de Sá Rosa e Silva argued that when the diagnosis is already known, waiting is indefensible. The correct approach is to begin low-dose physiologic estradiol at 12.5 micrograms per day — mimicking pre-pubertal hormone levels — and add progesterone only when the uterus requires protection. A second adolescent case, involving heavy bleeding ten months after a first period, called for intensive hormonal contraceptives dosed every eight to twelve hours before tapering, while also screening for underlying clotting disorders.
Cristina Laguna of Unicamp addressed a 37-year-old who had undergone full hysterectomy for endometriosis and was experiencing surgical menopause. She challenged the notion that hormone therapy must be delayed after such surgery: there is no mandatory waiting period, she said. The decision should be individualized based on the woman's age and symptoms — start when she needs it.
The panel then turned to premature ovarian insufficiency, emphasizing that this condition operates under entirely different logic than natural menopause. The "window of opportunity" framework does not apply. Hormone therapy should be maintained until the age at which menopause would naturally have occurred, treating the condition as the distinct endocrine disorder it is.
For women with systemic lupus erythematosus, Gustavo Soares noted that those with low disease activity and no antiphospholipid syndrome can use hormone therapy with reasonable safety. In polycystic ovary syndrome, the conversation centered on cardiovascular risk, lifestyle intervention, and the levonorgestrel-releasing IUD as an alternative to oral contraceptives.
Across every case, the panel returned to the same principle: blanket rules fail individual patients. The evidence is there — but it must be read in the context of the specific woman sitting across from you.
At the 63rd Brazilian Congress of Gynecology and Obstetrics in May 2026, a panel of specialists gathered to untangle what works from what merely sounds right in hormone therapy for women's endocrine conditions. The roundtable, led by Edmund Baracat from the University of São Paulo's medical school, moved through six clinical scenarios—each one a knot that needed careful untying.
The first case involved a teenager with Turner syndrome who had never menstruated. The conventional wisdom says to wait until age 16 before investigating primary amenorrhea, but Ana Carolina Japur de Sá Rosa e Silva, presenting from USP's Ribeirão Preto campus, made clear that this rule breaks down when you already know what's wrong. In Turner syndrome, she explained, you start estradiol early—at a physiologic dose of 12.5 micrograms per day, mimicking the hormone levels of a girl before puberty begins. Progesterone comes later, only when the uterus needs protection or when bleeding needs to be induced. The panel also discussed a second adolescent case: heavy bleeding that erupted ten months after her first period. Here the approach shifted to intensive hormonal contraceptives containing 30 micrograms of ethinylestradiol, dosed every eight or twelve hours for a week, then scaled back to daily maintenance. The logic was straightforward—control the bleeding while investigating for clotting disorders that might lurk beneath.
The conversation then moved to a 37-year-old woman who had her uterus, fallopian tubes, and ovaries removed because endometriosis had become unbearable. After surgery, she developed the hot flashes and night sweats of surgical menopause. Cristina Laguna from Unicamp challenged another piece of conventional thinking: the idea that you need to wait some prescribed interval before starting hormone therapy after hysterectomy for endometriosis. There is no such waiting period, she said. What matters is individualizing the decision based on the woman's age and symptoms. Start when she needs it.
A third case involved a woman of reproductive age struggling with infertility and FSH levels that signaled premature ovarian insufficiency—the ovaries failing years before they should. This diagnosis changes the entire framework. The "window of opportunity" concept, borrowed from natural menopause, does not apply here. Instead, hormone therapy should continue until the age when menopause would naturally occur, following the same safety rules as always. The distinction matters because it means these younger women are not being treated as early menopausal; they are being treated as having a specific endocrine condition that requires sustained support.
The final presentations tackled two conditions often tangled together with cardiovascular risk. In systemic lupus erythematosus, Gustavo Soares from the Federal University of Rio Grande do Norte noted that women without active disease (a SLEDAI score of 2 or lower) and without antiphospholipid syndrome can use hormone therapy with reasonable safety. Disease flares are rare in these circumstances. For polycystic ovary syndrome, the focus narrowed to contraceptive choice in women at higher cardiovascular risk, with particular attention to lifestyle changes and the levonorgestrel-releasing intrauterine system as an alternative to oral pills.
What emerged across all six cases was a single principle: stop applying one-size-fits-all rules to conditions that demand precision. Wait for age 16 to investigate amenorrhea—except when you already know the diagnosis. Avoid hormone therapy after endometriosis surgery—except when the woman is suffering and needs it now. Apply the menopause window of opportunity—except when you are treating premature ovarian insufficiency, which follows different logic entirely. The congress, held in Belo Horizonte from May 27 to 30, brought together gynecologists, obstetricians, residents, and medical students to hash out these distinctions. The message was clear: evidence matters, but so does the individual woman sitting in front of you.
Notable Quotes
Do not wait until age 16 to investigate primary amenorrhea when a diagnosis like Turner syndrome is already established— Ana Carolina Japur de Sá Rosa e Silva, USP Ribeirão Preto
There is no need to wait a specific period before starting hormone therapy in women after hysterectomy for endometriosis, provided the decision is individualized— Cristina Laguna, Unicamp
The Hearth Conversation Another angle on the story
Why does the age-16 rule for investigating amenorrhea need to be broken in Turner syndrome?
Because waiting is pointless when you already know what caused it. The rule exists to catch hidden problems in girls with no diagnosis. But Turner syndrome is diagnosed early, often through prenatal screening or childhood growth concerns. Delaying hormone therapy just means the girl stays without puberty longer than necessary.
So the dose of estradiol matters as much as the timing?
Absolutely. You start low—12.5 micrograms—to mimic what a younger girl's body produces naturally. If you jump to adult doses, you risk closing growth plates too fast and triggering other changes before the body is ready. It's about pacing, not just starting.
The endometriosis case seemed to overturn a waiting period. Is that new thinking?
Not entirely new, but it challenges a habit. Doctors used to think you needed to let the surgical site heal, or that hormone therapy might reactivate endometriosis. The evidence doesn't support that caution. If a woman is miserable with menopausal symptoms after hysterectomy, there's no reason to make her wait.
What makes premature ovarian insufficiency different from natural menopause in terms of treatment?
Age, mainly. A 35-year-old with premature ovarian insufficiency needs hormone support until age 50 or 51—when her peers would naturally reach menopause. She's not early menopausal; she's got a condition that needs managing for another 15 years. The window of opportunity concept doesn't apply because there's no window closing—there's a long runway ahead.
And in lupus, when is hormone therapy actually safe?
When the disease is quiet and there's no antiphospholipid syndrome. A SLEDAI score of 2 or lower means minimal inflammation. In those cases, flares from hormone therapy are rare. It's not that lupus patients can never have hormones—it's that you need to know the disease state first.
The polycystic ovary syndrome discussion seemed to focus on cardiovascular risk. Why?
Because women with PCOS already have metabolic problems—insulin resistance, inflammation, higher cholesterol often. Add a hormonal contraceptive with estrogen, and you're potentially adding more cardiovascular stress. So you think harder about whether a pill is the right choice, or whether something like a levonorgestrel IUD—which avoids systemic estrogen—might be better.